title: Optimized preparation method of platelet-concentrated plasma and noncoagulating platelet-derived factor concentrates: maximization of platelet concentration and removal of fibrinogen.
abstract: Platelet-rich plasma (PRP) has been clinically used as an easily prepared growth factor cocktail that can promote wound healing, angiogenesis, and tissue remodeling. However, the therapeutic effects of PRP are still controversial, due partly to the lack of optimized and standardized preparation protocols. We used whole blood (WB) samples to optimize the preparation protocols for PRP, white blood cell-containing (W-PRP), platelet-concentrated plasma (PCP), and noncoagulating platelet-derived factor concentrate (PFC). PRP and W-PRP were most efficiently collected by 10 min centrifugation in a 15-mL conical tube at 230-270 g and 70 g, respectively. To prepare PCP, platelets were precipitated by centrifugation of PRP at >2300 g, 90% of supernatant plasma was removed, and the platelets were resuspended. For preparation of noncoagulating PFC, the supernatant was replaced with one-tenth volume of saline, followed by platelet activation with thrombin. Platelet (before activation) and platelet-derived growth factor (PDGF)-BB (after activation) concentrations in PCP were approximately 20 times greater than those in WB, whereas PFC contained a 20-times greater concentration of platelets before platelet activation and a 50-times greater concentration of PDGF-BB without formation of a fibrin gel after platelet activation than WB. Surprisingly, total PDGF-BB content in the PFC was twice that of activated WB, which suggested that a substantial portion of the PDGF-BB became trapped in the fibrin glue, and replacement of plasma with saline is crucial for maximization of platelet-derived factors. As an anticoagulant, ethylene di-amine tetra-acetic acid disodium inhibited platelet aggregation more efficiently than acid citrate dextrose solution, resulting in higher nonaggregated platelet yield and final PDGF-BB content. These results increase our understanding of how to optimize and standardize preparation of platelet-derived factors at maximum concentrations.
authors.affiliation: Department of Plastic Surgery, University of Tokyo, Tokyo, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Araki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Jona
authors.forename: Hitomi
authors.initials: H
authors.lastname: Eto
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Aoi
authors.forename: Harunosuke
authors.initials: H
authors.lastname: Kato
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Suga
authors.forename: Kentaro
authors.initials: K
authors.lastname: Doi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yatomi
authors.forename: Kotaro
authors.initials: K
authors.lastname: Yoshimura
mesh_terms: D000328:Adult; D001779:Blood Coagulation Factors / Q000302:isolation & purification / Q000378:metabolism; D001781:Blood Component Removal / Q000379:methods / Q000592:standards*; D001792:Blood Platelets / Q000737:chemistry* / Q000378:metabolism; D002138:Calibration; D005260:Female; D005340:Fibrinogen / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D010976:Platelet Count; D010982:Platelet-Derived Growth Factor / Q000032:analysis / Q000302:isolation & purification* / Q000378:metabolism; D053657:Platelet-Rich Plasma / Q000737:chemistry / Q000378:metabolism / Q000502:physiology
chemical_list: D001779:Blood Coagulation Factors; D010982:Platelet-Derived Growth Factor; D005340:Fibrinogen